(Q46718477)

24 December 2017

title

The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma (English)

1 reference

24 December 2017

1 reference

Kazim Uygun

1

1 reference

24 December 2017

Gorkem Aksu

2

1 reference

24 December 2017

Irfan Cicin

3

1 reference

24 December 2017

Hakan Karagol

4

1 reference

24 December 2017

Zafer Kocak

5

1 reference

24 December 2017

Merdan Fayda

6

1 reference

24 December 2017

Ahmet Binici

7

1 reference

24 December 2017

Fernaz Uzunoglu

8

1 reference

24 December 2017

publication date

5 March 2008

1 reference

24 December 2017

published in

Medical Oncology

1 reference

24 December 2017

volume

25

1 reference

24 December 2017

issue

4

1 reference

24 December 2017

page(s)

408-414

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1007/s12032-008-9055-1

exact match

0 references

cites work

A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status

1 reference

12 December 2020

Second-line treatment for advanced non-small cell lung cancer: a systematic review

1 reference

12 December 2020

A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party. 101473.1044@compuserve.com

1 reference

12 December 2020

Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer

1 reference

12 December 2020

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

12 December 2020

Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials

1 reference

12 December 2020

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

12 December 2020

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

12 December 2020

Second-line therapeutic options in non-small-cell lung cancer

1 reference

12 December 2020

Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial

1 reference

12 December 2020

Non-small cell lung cancer: second-line and beyond

1 reference

12 December 2020

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment

1 reference

12 December 2020

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

12 December 2020

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

12 December 2020

Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial

1 reference

12 December 2020

Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice

1 reference

12 December 2020

Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel

1 reference

12 December 2020

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).

1 reference

12 December 2020

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

12 December 2020

Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial

1 reference

12 December 2020

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

12 December 2020

Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens

1 reference

12 December 2020

Salvage therapy in patients with advanced non-small cell lung cancer

1 reference

12 December 2020

Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline.

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study.

1 reference

12 December 2020

Is the second line data on the use of docetaxel in non-small cell lung cancer reproducible?

1 reference

12 December 2020

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

12 December 2020

Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer

1 reference

12 December 2020

Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial

1 reference

12 December 2020

Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial

1 reference

12 December 2020

Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial

1 reference

12 December 2020

10.1007/S12032-008-9055-1

Identifiers

DOI

1 reference

24 December 2017

PubMed ID

18320363

1 reference

24 December 2017